期刊文献+

甲磺酸帕珠沙星注射液治疗急性细菌感染的疗效研究 被引量:3

Clinical Study of Pazufloxacin Mesilate in Treatment of Acute Bacterial Infection
下载PDF
导出
摘要 目的 评价帕珠沙星治疗急性细菌感染的临床疗效和安全性。方法 采用随机、双盲、对照试验的方法,治疗组为甲磺酸帕珠沙星注射液,对照组为左氧氟沙星,每组各20例,纳入对象为呼吸道、泌尿道感染,甲磺酸帕珠沙星用量:轻度感染500mg Qd静滴;中度感染500mgBid静滴。左氧氟沙星用量:轻度感染200mgQd静滴;中度感染200mgBid静滴。疗程均为7~14d。结果 甲磺酸帕珠沙星的临床治愈率70.0%(14/20),有效率90.0%(18/20),细菌清除率87.5%(14/16);对照组左氧氟沙星分别为65.0%(13/20),90.0%(18/20),86.7%(13/15)。帕珠沙星和左氧氟沙星不良反应发生率均为8.7%。以上结果经统计学处理,差异均无统计学意义(P均〉0.05)。结论 甲磺酸帕珠沙星是治疗轻中度呼吸道、泌尿道感染有效、安全的抗菌药物。 Objective To evaluate efficacy and safety of pazufloxacin mesilate in treatment of acute bacterial infections. Method A randomized, double blind and controlled trial with 20 pairs of patients with respiratory and urinary tract bacterial infection were treated with pazufloxacin mesilate( treatment group)and levofloxacin (con- trol group)respectively. The dosage of pazufloxacin mesilate in treating low grade infection and midrange infec- tion was 500 mg once daily and twice daily intravenous drop infusion respectively for 7-14 days. And the dosage of levofloxacin in treating low grade infection and midrange infection was 200 mg once daily and twice daily in- travenous drop infusion respectively for 7-14 days. Result The results showed that the cure rate of pazufloxacin mesilate was 70. 0% (14/20), the effective rate was 90. 0% (18/20)and the bacterial clearance rate was 87.5% (14/16) ,while in levofloxacin group they were 65.0% (13/20) ,90. 0% (18/20) and 86.7% (13/15) respectively. The adverse reaction rates of both pazufloxacin mesilate and levofloxacin were 8.7%. There were no statistical significant differences( P 〉 0. 05 )between pazufloxacin mesilate and levofloxacin in overall results. Conclusion The study demonstrated pazufloxacin mesilate was an antibiotic of efficacy and safety in treating respiratory and urinary tract bacterial infection.
出处 《寄生虫病与感染性疾病》 CAS 2006年第4期161-164,共4页 Parasitoses and Infectious Diseases
关键词 甲磺酸帕珠沙星 左氧氟沙星 细菌感染 pazufloxacin mesilate levofloxacin bacterial infection
  • 相关文献

参考文献7

  • 1Takei M,Fukuda H,Kishii R,et al.Target preference of 15 quinolone against Staphylococcus aureus,based on antibacterial activities and target inhibition[J].Antimicrob Agents Chemother,2001,45:3544.
  • 2杨信怡,游雪甫.注射用帕珠沙星的药理研究和临床应用[J].国外医药(抗生素分册),2003,24(2):80-87. 被引量:59
  • 3Tanimura H,Uchiyama K,Endo S,et al.Clinical investigation and tissue concentrations of injectable pazufloxacin mesilate in patients with surgical infections[J].Japan J Chemother,2000,48:353.
  • 4Mitsuyama J,Miyazaki S,Ishii Y,et al.Antibacterial activity of a new injectable quinolone pazufloxacin mesilate in vitro and in vivo[J].Japan J Chemother,1999,47(Suppl 1):1.
  • 5Mikamo H,Sato Y,Hayasaki Y,et al.In vitro activities of pazufloxacin,an injectable new quinolone,against bacteria causing infections in obstertric and gynecological patients[J].Japan J Chemother,1999,47(Suppl 1):16.
  • 6Nishino T,Ikeda Y,Otsuki M,et al.In vitro and in vivo antibacterial activity of pazufloxacin mesilate,a new parenteral fluoroquinolone[J].Japan J Chemother,1999,47(Suppl 1):25.
  • 7Mitsuyama J,Takahata M,Yamashiro Y,et al.Antibacterial activity of a new injectable quinolone,pazufloxacin mesilate,in vitro and in vivo[J].Japan J Chemother,1999,47(Suppl 1):37.

二级参考文献1

  • 1Nakashima M Uemura K Kosuge K et al.Phase Ⅰ clinical study of pazufloxacin mesilate [J].Japan J Chemother,1999,47(1):141-141.

共引文献58

同被引文献50

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部